导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.06% | 3006/4407 |
| 近一周 | -2.06% | 3680/5016 |
| 近一月 | -4.40% | 1590/4972 |
| 近一季 | -5.48% | 1687/4811 |
| 近半年 | -6.21% | 3005/4547 |
| 近一年 | -2.89% | 2783/4077 |
| 近两年 | 39.70% | 1758/2754 |
| 近三年 | 18.68% | 1401/2082 |
| 成立以来 | 116.70% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.35% 2762/4961 |
2.98% 2958/5312 |
- - |
- - |
| 2025 | 17.50% 2377/4813 |
-1.63% 2717/3635 |
1.32% 2381/4076 |
18.92% 2226/4524 |
-0.85% 2684/4813 |
| 2024 | 12.83% 1209/3463 |
1.08% 899/2808 |
-2.07% 1133/3014 |
15.65% 1662/3129 |
-1.44% 1707/3463 |
| 2023 | -8.00% 973/2656 |
6.72% 656/2280 |
-3.89% 951/2385 |
-4.44% 1140/2515 |
-6.14% 1642/2655 |
| 2022 | -19.36% 839/2207 |
-13.90% 868/1919 |
5.31% 922/2016 |
-13.19% 856/2113 |
2.45% 932/2208 |
| 2021 | 1.82% 653/1822 |
-2.83% 711/1255 |
4.84% 842/1330 |
-1.79% 539/1466 |
1.77% 803/1822 |
| 2020 | 39.09% 341/1250 |
-4.80% 384/1028 |
14.23% 563/1067 |
17.48% 102/1164 |
8.88% 656/1184 |
| 2019 | 36.90% 347/1092 |
28.22% 323/754 |
-4.99% 450/804 |
1.57% 386/850 |
10.63% 112/918 |
| 2018 | -26.66% 391/834 |
- - |
- - |
- - |
-11.26% 273/691 |
| 2017 | 5.21% 360/714 |
- - |
- - |
- - |
- - |
| 2016 | -13.74% 328/605 |
- - |
- - |
- - |
- - |
| 2015 | 16.83% 133/575 |
- - |
- - |
- - |
- - |
| 2014 | 42.51% 118/237 |
- - |
- - |
- - |
- - |
| 2013 | -1.98% 70/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 中银沪深300等权重指数 VS. 长安沪深300非周期A(740101) |